Clinical Trial Update: Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mesenchymal stem cell infusion to prevent acute graft-versus-host disease in transplant patients; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Relapse of Hematologic Malignancy

Drugs mentioned

• Mesenchymal Stem Cell Infusion

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Graft-versus-host Disease, Relapse | Phase 2 | Status: UNKNOWN